Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.
- IPO to raise $8 million at $0.25 per share
- Device targets behavioural symptoms of Alzheimer’s via neuromodulation
- Phase 1 trial showed safety and preliminary efficacy
- Two Phase 2 trials underway with ethics approval
- Exclusive intellectual property licensed from UniQuest
Ceretas IPO Aims to Propel Alzheimer's Ultrasound Device
Ceretas Limited (ASX:CTS) is stepping into the spotlight with an $8 million initial public offering (IPO), aiming to fund the next phase of clinical trials and further development of its portable, non-invasive therapeutic ultrasound device designed to treat Alzheimer’s disease. The company plans to issue 32 million shares at 25 cents each, with trading expected to commence on the ASX by late July 2026.
The Ceretas Device leverages focused ultrasound technology to modulate neural circuits implicated in memory, cognition, and mood, targeting the behavioural and psychological symptoms of dementia (BPSD) that afflict the majority of Alzheimer’s patients. This neuromodulation approach, distinct from existing pharmacotherapies, is designed to be delivered in a 25-minute session without surgery or anaesthesia, making it suitable for hospitals, outpatient clinics, and aged care facilities.
Clinical Progress and Trial Pipeline
These trials collectively aim to refine treatment protocols, validate efficacy, and inform a pivotal Phase 3 trial and regulatory submissions. The company is preparing to commence patient recruitment immediately following its ASX listing.
Intellectual Property and Regulatory Strategy
Ceretas holds an exclusive licence to a portfolio of intellectual property developed over a decade at The University of Queensland and QBI, including granted patents across major jurisdictions such as the US, Australia, Canada, and Europe. Upon completion of the IPO, full ownership of this IP will be assigned to Ceretas by UniQuest, the university’s commercialisation arm.
The company’s regulatory focus is the US FDA, with plans to pursue CE Marking in Europe and TGA registration in Australia. Early engagement with regulatory advisers aims to clarify device classification and approval pathways. Ceretas also intends to develop reimbursement strategies in parallel, recognising that regulatory approval alone does not guarantee market access.
Financial Position and Use of Proceeds
Since incorporation in October 2024, Ceretas has raised seed capital and secured a $2.39 million grant from the Australian Government’s Medical Research Future Fund under the CUREator+ Dementia initiative. The company reported a loss of $183,380 for the period ending June 2025, reflecting early-stage development costs and administrative expenses.
The IPO proceeds will primarily fund completion of the CERE-CALM Phase 2 trial (35% of funds), next-generation device development (13%), pre-clinical studies on blood-brain barrier opening (4%), regulatory and market access strategies (6%), and working capital (27%). The company cautions that additional funding will be necessary to support Phase 3 trials and commercialisation efforts beyond the IPO.
Risks and Governance
Ceretas is an early-stage venture with no commercial revenue and faces typical biotech risks including clinical trial outcomes, regulatory approvals, intellectual property protection, manufacturing scale-up, and market acceptance. The company’s shares will be subject to escrow arrangements affecting liquidity for up to 24 months post-listing.
The board comprises experienced executives and non-executive directors with backgrounds in medical technology, finance, and research. Directors and key management hold shares and incentive options aligned with shareholder interests.
The Road Ahead
With its IPO underway, Ceretas is poised to advance a novel therapeutic ultrasound platform that could address significant unmet needs in Alzheimer’s disease, particularly behavioural symptoms poorly served by existing treatments. The success of its Phase 2 trials and subsequent regulatory engagements will be pivotal in determining the company’s trajectory. Investors should weigh the speculative nature of the business against the potential for innovation in a large and growing neurodegenerative disease market.
Bottom Line?
Ceretas’ IPO marks a critical funding milestone, but its future hinges on clinical trial success and regulatory approvals in a challenging medtech landscape.
Questions in the middle?
- Will Ceretas’ Phase 2 trials confirm the preliminary behavioural benefits observed in Phase 1?
- How will regulatory agencies classify the Ceretas Device, and what evidence will be required for approval?
- What partnerships or funding sources might Ceretas pursue to finance the costly Phase 3 trial and commercial launch?